Option chain shows key data for Jowell Global's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Jowell Global.

Jowell Global (NASDAQ:JWEL) Stock, Option Chain

Jowell Global

Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.

xr:d:DAFlJKNXbrw:2,j:4527636209394207909,t:23060712

News

Intraday Update

Markets

Movers

Trading Ideas

AEMD

AIRJ

AONC

ASNS

ASST

BASE

BNRG

CHSN

CLEU

CODX

FDMT

FIVE

FRES

FRGT

GIII

HALO

ISPC

JWEL

KITT

LIVN

LULU

MITQ

MSGM

NDRA

OLLI

ONMD

PHAR

PLTN

PXDT

REPL

RYDE

SCWX

SMAR

SNBR

TRSG

UNFI

VIRI

VNDA

VRAX

VTYX

XPOF

ZCAR

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

jobless unemployed shutter

Earnings

Eurozone

Commodities

Dow Surges 100 Points; US Initial Jobless Claims Rise

xr:d:DAFlOmGuDsM:2,j:5218938843108744318,t:23060810

Pre-Market Outlook

MASI

NVVE

Why Smartsheet Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

Jowell Global Ltd

8 analysts have shared their evaluations of Riot Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Riot Platforms and provided 12-month price targets. The average target is $16.81, accompanied by a high estimate of $23.00 and a low estimate of $11.00. This current average reflects an increase of 9.01% from the previous average price target of $15.42. 
<img src="https://www.benzinga.com/files/images/story/2024/1734436847_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Riot Platforms. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$23.00</td>
<td>-</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Chase White</td>
<td>Compass Point</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$17.50</td>
<td>$15.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Mike Colonnese</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$22.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Paul Golding</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Riot Platforms. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Riot Platforms compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Riot Platforms's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Riot Platforms's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RIOT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Riot Platforms analyst ratings.</a>
<h2>Unveiling the Story Behind Riot Platforms</h2>
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining; Data Center Hosting and Engineering. It generates maximum revenue from the Bitcoin Mining segment which generates revenue from the Bitcoin the company earns through its mining activities.
<h3>Riot Platforms's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Riot Platforms's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 63.39% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Riot Platforms's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -182.06%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Riot Platforms's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -5.79%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Riot Platforms's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.47%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Riot Platforms's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

RIOT

8 Analysts Have This To Say About Riot Platforms

Analysts' ratings for Inari Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NARI#NASDAQ">NARI</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $60.67, a high estimate of $75.00, and a low estimate of $46.00. Marking an increase of 5.33%, the current average surpasses the previous average price target of $57.60. 
<img src="https://www.benzinga.com/files/images/story/2024/1734436840_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Inari Medical's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steve Lichtman</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$75.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$50.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$67.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$46.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Inari Medical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Inari Medical compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Inari Medical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Inari Medical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NARI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Inari Medical analyst ratings.</a>
<h2>About Inari Medical</h2>
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
<h3>Inari Medical's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Inari Medical's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 21.39%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Inari Medical's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -11.97%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Inari Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -4.28%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Inari Medical's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.68%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.08, Inari Medical adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NARI

Demystifying Inari Medical: Insights From 6 Analyst Reviews

NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) underwent analysis by 13 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $51.54, with a high estimate of $58.00 and a low estimate of $44.00. This current average represents a 15.4% decrease from the previous average price target of $60.92. 
<img src="https://www.benzinga.com/files/images/story/2024/1734436832_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A clear picture of NEXTracker's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$54.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Gus Richard</td>
<td>Northland Capital Markets</td>
<td>Announces</td>
<td>Outperform</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>Dimple Gosa</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ben Kallo</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Mark Strouse</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$50.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Jordan Levy</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Ameet Thakkar</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$44.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to NEXTracker. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of NEXTracker compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into NEXTracker's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NXT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NEXTracker analyst ratings.</a>
<h2>Discovering NEXTracker: A Closer Look</h2>
Nextracker (and its subsidiaries) is a leading provider of intelligent, integrated solar tracker and software solutions used in utility-scale and distributed generation solar projects around the world. Nextracker's products enable solar panels in utility-scale power plants to follow the sun's movement across the sky and optimize plant performance. Nextracker has operations in the United States, Mexico, Spain and other countries in Europe, India, Australia, the Middle East, Africa, and Brazil.
<h3>Financial Milestones: NEXTracker's Journey</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: NEXTracker's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 10.85%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: NEXTracker's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 18.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): NEXTracker's ROE excels beyond industry benchmarks, reaching 9.67%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): NEXTracker's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.28% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.12, NEXTracker adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On NEXTracker Through 13 Analysts

Across the recent three months, 9 analysts have shared their insights on Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Spire and provided 12-month price targets. The average target is $71.83, accompanied by a high estimate of $80.00 and a low estimate of $60.50. Marking an increase of 1.8%, the current average surpasses the previous average price target of $70.56. 
<img src="https://www.benzinga.com/files/images/story/2024/1734436823_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Spire by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Gaugler</td>
<td>Janney Montgomery Scott</td>
<td>Announces</td>
<td>Neutral</td>
<td>$73.00</td>
<td>-</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Selman Akyol</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$69.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>William Appicelli</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Sarah Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Gabriel Moreen</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Paul Fremont</td>
<td>Ladenburg Thalmann</td>
<td>Lowers</td>
<td>Sell</td>
<td>$60.50</td>
<td>$65.50</td>
</tr>
<tr>
<td>Sarah Akers</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$76.00</td>
<td>$70.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Spire. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Spire compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Spire's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Spire's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Spire analyst ratings.</a>
<h2>Delving into Spire's Background</h2>
Spire Inc is a public utility holding company with three reportable business segments: Gas Utility, Gas Marketing and Midstream. The Gas Utility segment includes the regulated operations of Laclede Gas, Alabama Gas Corporation ('Alagasco') changed its name to Spire Alabama Inc. effective September 1, 2017, and Laclede Gas Company changed its name to Spire Missouri Inc. effective August 30, 2017. The Gas Utility segment generates a majority of the company's revenue but is subject to seasonal fluctuations. The Gas Marketing segment includes Laclede Energy Resources, Inc, whose operations include the marketing of natural gas and related activities on a non-regulated basis and the Midstream segment includes transportation and storage of natural gas. Maximum revenue from residential area.
<h3>Unraveling the Financial Story of Spire</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Spire faced challenges, resulting in a decline of approximately -5.35% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Utilities sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Spire's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.04%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Spire's ROE excels beyond industry benchmarks, reaching -0.97%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Spire's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.27%, the company showcases efficient use of assets and strong financial health.
Debt Management: Spire's debt-to-equity ratio surpasses industry norms, standing at 1.57. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Spire Stock

The stark contrast between traditional real estate investments and cryptocurrency markets has come into sharp focus as Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) crossed the $100,000 mark, while New York City&#8217;s real estate market maintains steady but modest growth, according to recent market data.
What Happened: New York City&#8217;s median home prices reached $785,000 in early 2024, showing a measured recovery from the slight dip to $764,000 in 2023, according to StreetEasy data cited by the NYC Comptroller&#8217;s office. 
The city&#8217;s real estate appreciation has been notably conservative, with prices rising approximately 16% since the pre-pandemic period, significantly lower than the national average of 42%.
DoorLoop, a rental property management software company, reports that NYC real estate maintains an annual average appreciation rate of 6%, representing a stable but modest return for traditional investors.
Meanwhile, Bitcoin&#8217;s price trajectory tells a dramatically different story, currently trading at $106,522. The cryptocurrency&#8217;s historical performance has been marked by extreme volatility, with annual returns ranging from gains of 1,369% in 2017 to losses of 73% in 2018.
In May, Michael Saylor, Executive Chairman of MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), drew an intriguing parallel between the two assets in an interview with Yahoo Finance. 
&#8220;New York City is the endgame for people that want to live in the greatest city in North America. Bitcoin is the endgame for anybody that wants to own the greatest property in the 21st century,&#8221; Saylor stated, referring to Bitcoin as &#8220;the apex property of the human race.&#8221;
Bitcoin&#8217;s journey since 2009 has been remarkable, with its price soaring from just $0.0009 per coin in the first transaction to approximately $106,000 in 2024, reflecting a compound annual growth rate of 244.32% over 15 years.
Early on, Bitcoin&#8217;s price remained under $1 until 2011, when it reached $0.2972, and surged to $946.48 by 2013. Despite extreme volatility, such as the 1,369% surge in 2017 and a 73.48% drop in 2018, Bitcoin has shown resilience and strong long-term growth. As of 2024, year-to-date gains stand at 141.48%, highlighting its continued dominance in the market.
See Also: <a href="https://www.benzinga.com/trading-ideas/movers/24/12/42522084/bitcoin-ethereum-dogecoin-settle-down-amid-growing-talks-of-a-strategic-btc-reserve-top-analyst-sees-prospect-of-apex-crypto-hitting-110k-this-week">Bitcoin, Ethereum, Dogecoin Settle Down Amid Growing Talks Of A Strategic BTC Reserve: Top Analyst Sees Prospect Of Apex Crypto Hitting $110K This Week</a>
Eric Trump, Executive Vice President of the Trump Organization and son of President-elect Donald Trump, shared his perspective at the Bitcoin MENA 2024 Conference during an interview <a href="https://x.com/BitcoinMagazine/status/1866568436115239400?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1866568436115239400%7Ctwgr%5E4141364f2fb9a63b995234a19a19603559d4e270%7Ctwcon%5Es1_c10&amp;ref_url=https%3A%2F%2Fbitcoinmagazine.com%2Fmarkets%2Feric-trump-states-bitcoin-is-the-ultimate-hedge-for-real-estate-investors">with</a> Bitcoin Magazine. Despite his background in real estate, Trump acknowledged cryptocurrency&#8217;s advantages over physical assets, particularly noting real estate&#8217;s illiquidity and higher transaction costs.
The investment comparison highlights key <a href="https://www.benzinga.com/markets/24/11/42073064/why-real-estate-might-outshine-gold-and-bitcoin-as-a-long-term-investment">differences in accessibility and costs</a>. Real estate purchases involve fees including taxes, realtor commissions, and property improvements, while Bitcoin transactions typically require minimal fees for purchase and transfer to self-custody.
For investors weighing their options, the choice between NYC real estate and Bitcoin represents a fundamental decision between steady, traditional appreciation and the potential for <a href="https://www.benzinga.com/24/12/42519107/if-you-invested-1000-in-bitcoin-when-the-first-bitcoin-etf-was-filed-heres-how-much-youd-have-today">dramatic gains coupled with significant risk</a>. 
The emergence of Bitcoin ETFs has significantly increased retail investor interest, with prominent offerings such as iShares Bitcoin Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NASDAQ">IBIT</a>), Grayscale Bitcoin Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTC#NYSE">GBTC</a>), Fidelity Wise Origin Bitcoin Fund (BATS:<a class="ticker" href="https://www.benzinga.com/stock/FBTC#BATS">FBTC</a>), ARK 21Shares Bitcoin ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKB#BATS">ARKB</a>), Bitwise Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITB#NYSE">BITB</a>), Grayscale Bitcoin Mini Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTC#NYSE">BTC</a>), ProShares Bitcoin ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BITO#NYSE">BITO</a>), and Volatility Shares Trust 2x Bitcoin Strategy ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/BITX#BATS">BITX</a>), providing various options for investors seeking exposure to the cryptocurrency market.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42488357/homebuilders-2025-outlook-more-cautious-less-constructive-analyst-says">Homebuilders 2025 Outlook: &#8216;More Cautious, Less Constructive,&#8217; Analyst Says</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Real Estate

$BTC

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

BITO

BITX

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

GBTC

IBIT

MSTR

Michael Saylor Compared Bitcoin To New York Real Estate: Where Are Investors Winning The 'Endgame?'

Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) underwent analysis by 12 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Shoals Technologies Gr, presenting an average target of $10.88, a high estimate of $46.00, and a low estimate of $5.00. Witnessing a positive shift, the current average has risen by 24.77% from the previous average price target of $8.72.
<img src="https://www.benzinga.com/files/images/story/2024/1734436816_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Shoals Technologies Gr among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Percoco</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Overweight</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Lee</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Dimple Gosal</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Kashy Harrison</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Joseph Osha</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Stephen Biggar</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Jeffrey Osborne</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Paul Coster</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Praneeth Satish</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Christine Cho</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Vikram Bagri</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$5.50</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Shoals Technologies Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Shoals Technologies Gr compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Shoals Technologies Gr's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Shoals Technologies Gr's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SHLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Shoals Technologies Gr analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Shoals Technologies Gr's Background</h2>
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.
<h3>Financial Insights: Shoals Technologies Gr</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Shoals Technologies Gr's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -23.88%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Shoals Technologies Gr's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -0.26%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Shoals Technologies Gr's ROE excels beyond industry benchmarks, reaching -0.05%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Shoals Technologies Gr's ROA stands out, surpassing industry averages. With an impressive ROA of -0.03%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Shoals Technologies Gr's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.26.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SHLS

Breaking Down Shoals Technologies Gr: 12 Analysts Share Their Views

Large Cap

Health Care

Contracts

General

Becton, Dickinson And Babson Diagnostics Announced An Expansion Of Fingertip Blood Collection And Testing Technologies For Use By U.S. Health Systems And Other Large Provider Networks In Settings Like Urgent Cares, Doctor Offices, And Other Ambulatory Care Settings

During the last three months, 10 analysts shared their evaluations of Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Freshworks, presenting an average target of $17.4, a high estimate of $24.00, and a low estimate of $11.00. This upward trend is evident, with the current average reflecting a 3.02% increase from the previous average price target of $16.89.
<img src="https://www.benzinga.com/files/images/story/2024/1734436809_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Freshworks by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$19.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$13.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Freshworks. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Freshworks compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Freshworks's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Freshworks's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FRSH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Freshworks analyst ratings.</a>
<h2>All You Need to Know About Freshworks</h2>
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.
<h3>A Deep Dive into Freshworks's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Freshworks showcased positive performance, achieving a revenue growth rate of 21.51% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Freshworks's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -16.06%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.66%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.92%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Freshworks's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FRSH

Forecasting The Future: 10 Analyst Projections For Freshworks

JP Morgan analyst Allen Gong downgrades TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) from Overweight to Neutral and lowers the price target from $116 to $75.

Downgrades

Price Target

TMDX

JP Morgan Downgrades TransMedics Gr to Neutral, Lowers Price Target to $75

JP Morgan analyst Anthony Paolone upgrades AvalonBay Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVB#NYSE">AVB</a>) from Neutral to Overweight and raises the price target from $247 to $262.

Upgrades

JP Morgan Upgrades AvalonBay Communities to Overweight, Raises Price Target to $262

JP Morgan analyst Anthony Paolone upgrades Veris Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRE#NYSE">VRE</a>) from Underweight to Neutral and raises the price target from $14 to $17.

JP Morgan Upgrades Veris Residential to Neutral, Raises Price Target to $17

Guidance

Pfizer Reaffirms FY24 Outlook For Revenue Of $61B – $64B (Est $62.974B), Adj EPS Of $2.75 – $2.95 (Est $2.92)

Stifel analyst Adam Borg upgrades Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from Hold to Buy and raises the price target from $95 to $136.

Stifel Upgrades Cloudflare to Buy, Raises Price Target to $136

Endeavour Silver Says Guanaceví Processing Resumed To Full Capacity This Week After Trunnion Failure In August

<ul>
<li>The study demonstrated that PKU GOLIKE, administered as the last daily dose and compared to standard amino acid protein substitutes, improved metabolic control by reducing harmful phenylalanine (Phe) levels and increasing beneficial tyrosine (Tyr) levels, both essential for brain function and metabolic health.</li>
<li>At the end of the one-week treatment period, patients receiving PKU GOLIKE as the last daily protein substitute dose showed a statistically significant reduction in blood Phe levels compared to those receiving standard amino acid substitutes (P=0.0002) and a statistically significant increase in blood Tyr levels (P=0.0113). Compared to baseline levels measured prior to the start of treatment, the PKU GOLIKE group achieved an average 17.8% reduction in blood Phe levels (P=0.0484) and an average 33.8% increase in blood Tyr levels (P=0.0008) upon awakening after the overnight fasting period. In comparison, when treated with standard amino acid protein substitutes, the same patients experienced an average 27.6% increase in blood Phe levels (P=0.0063) and no significant improvement in blood Tyr levels. Blood sample analysis at three early morning time points across the two groups revealed no significant differences in peak Phe levels upon reawakening in either group.</li>
</ul>

Biotech

ETON

Eton Pharmaceuticals Announced The Full Readout From The Clinical Trial Evaluating PKU GOLIKE As A Protein Substitute For Phenylketonuria In Patients During Prolonged Fasting Periods

Piper Sandler analyst Patrick Moley initiates coverage on Hut 8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) with a Overweight rating and announces Price Target of $33.

Initiation

Piper Sandler Initiates Coverage On Hut 8 with Overweight Rating, Announces Price Target of $33

Pfizer Says First Phase Of Manufacturing Optimization Program On Track To Deliver Initial Net Cost Savings In The Latter Part Of 2025

Pfizer Says It Achieved Goal Of $4B In Net Cost Savings Through 2024; Anticipates Additional $500M In Savings In 2025 From Ongoing Cost Realignment Program

Management

AIRS

AirSculpt Technologies Has Appointed Yogi Jashnani As Chief Executive Officer And A Member Of The Board Of Directors. He Succeeds Dennis Dean, Interim CEO And CFO Who Will Continue As CFO, All Effective January 7, 2025

Jefferies analyst James Heaney downgrades Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Buy to Hold and lowers the price target from $40 to $32.

MTCH

Jefferies Downgrades Match Group to Hold, Lowers Price Target to $32

China New Year holiday spending soars to pre-pandemic levels

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!



Moving stocks this morning are heaving trading, earnings reports, a stock offering and more.



Let&rsquo;s get into this news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Virax Biolabs (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrax-stock-quote/">VRAX</a>) stock is rocketing close to 158% alongside heavy pre-market trading.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are soaring more than 94% with strong early morning trading.</li>



<li>Logistic Properties (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lpa-stock-quote/">LPA</a>) stock is surging over 50% after <a href="https://www.nasdaq.com/press-release/logistic-properties-americas-ring-opening-bell-new-york-stock-exchange-2024-05-30">recently going public</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) shares are gaining more than 27% with heavy trading this morning.</li>



<li>iSpecimen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ispc-stock-quote/">ISPC</a>) stock is increasing over 25% with strong trading on Thursday morning.</li>



<li>Nanoviricides (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nnvc-stock-quote/">NNVC</a>) shares are rising nearly 19% without any clear news on Thursday.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is heading 18% higher despite a lack of news this morning.</li>



<li>Vanda Pharmaceuticals(NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/">VNDA</a>) shares are climbing more than 16% as it takes part in a <a href="https://www.nasdaq.com/press-release/vanda-pharmaceuticals-announces-participation-jefferies-2024-global-healthcare">global healthcare conference starting today</a>.</li>



<li>Motorsport Games (NASDAQ:<a href="https://investorplace.com/stock-quotes/msgm-stock-quote/">MSGM</a>) stock is jumping over 15% after <a href="https://www.nasdaq.com/press-release/motorsport-games-regains-compliance-nasdaq-listing-rules-2024-06-05">regaining listing compliance</a>.</li>



<li>8&times;8 (NASDAQ:<a href="https://investorplace.com/stock-quotes/eght-stock-quote/">EGHT</a>) shares are up more than 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is plummeting almost 45% <a href="https://investorplace.com/2024/06/why-is-actelis-networks-asns-stock-up-689-today/">after a massive rally yesterday</a>.</li>



<li>Jowell Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/jwel-stock-quote/">JWEL</a>) shares are diving over 23% after a major rally on Wednesday.</li>



<li>Sprinklr (NYSE:<a href="https://investorplace.com/stock-quotes/cxm-stock-quote/">CXM</a>) stock is tumbling more than 21% after <a href="https://www.nasdaq.com/press-release/sprinklr-announces-first-quarter-fiscal-2025-results-and-appoints-trac-pham-co-chief">cutting its revenue outlook</a>.</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) shares are taking a 19% beating after rallying in the prior day of trading.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is sliding over 17% as it <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-162-today/">comes off of a recent rally</a>.</li>



<li>Helius Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) shares are dropping more than 17% despite <a href="https://www.nasdaq.com/press-release/microcap-rodeos-spring-summer-conference-june-6th-2024-25-presenting-companies-2024">taking part in a conference today</a>.</li>



<li>InMed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/inm-stock-quote/">INM</a>) stock is falling close to 17% on Thursday morning.</li>



<li>Nuvve (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvve-stock-quote/">NVVE</a>) shares are decreasing over 16% after a rally yesterday.</li>



<li>Renalytix (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnlx-stock-quote/">RNLX</a>) stock is slipping more than 16% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318376664&amp;type=PDF&amp;symbol=RNLX&amp;cdn=50b6d5e78c92d2a587a022cdac0add19&amp;companyName=Renalytix+plc&amp;formType=S-3&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-05">proposed secondary stock sale</a>.</li>



<li>Five Below (NASDAQ:<a href="https://investorplace.com/stock-quotes/five-stock-quote/">FIVE</a>) shares close out our pre-market stock movers down over 16% after <a href="https://finance.yahoo.com/news/five-below-five-q1-earnings-211505510.html">missing Q1 estimates</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-6th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

AIRYY

BABA

BZUN

CHEAF

CHKIF

DADA

EGHT

GXYEF

HSDT

HTHT

IMAX

IMXCF

LKNCY

MCHI

MCHVF

MCHVY

MLCO

MLGO

NNVC

RNLX

SCHYF

SCHYY

SJMHF

SJMHY

SXTP

TOUR

TRIP

WYNMF

WYNMY

WYNN

YUMC

BARK

Big 5 Sporting Goods Corporation - Common Stock

Big 5 Sporting Goods

Barnes & Noble Education, Inc Common Stock

Barnes & Noble Education

Boqii Holding Limited American Depositary Shares, representing Class A Ordinary Shares

Comments

Jowell Global

Jowell Global (JWEL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga